Is disorganized schizophrenia a predictor of treatment resistance? Evidence from an observational study by Ortiz, Bruno Bertolucci et al.
BRIEF COMMUNICATION
Is disorganized schizophrenia a predictor of treatment
resistance? Evidence from an observational study
Bruno Bertolucci Ortiz,1,2 Gerardo Maria de Arau´jo Filho,3,4 Ary Gadelha de Alencar Araripe Neto,1,3
Daiane Medeiros,2 Rodrigo Affonseca Bressan1,3
1Schizophrenia Program, Universidade Federal de Sa˜o Paulo (UNIFESP), Sa˜o Paulo, SP, Brazil. 2Department of Psychiatry, Hospital das
Clı´nicas Luzia de Pinho Melo, Associac¸a˜o Paulista para o Desenvolvimento da Medicina (SPDM), Mogi das Cruzes, SP, Brazil.
3Interdisciplinary Laboratory of Clinical Neurosciences, UNIFESP, Sa˜o Paulo, SP, Brazil. 4Department of Psychiatry and Medical Psychology,
Sa˜o Jose´ do Rio Preto Medical School, Sa˜o Jose´ do Rio Preto, SP, Brazil.
Objective: To investigate whether inpatients with disorganized schizophrenia are more resistant to
treatment.
Method: Eighty-five inpatients were assessed at admission and at discharge for schizophrenia
subtype, symptom severity, and treatment resistance criteria.
Results: Disorganized patients were significantly more treatment-resistant than paranoid patients
(60%, p = 0.001), and presented worse scores on the Positive and Negative Syndrome Scale
(PANSS), the Clinical Global Impression Scale (CGI-S), and the Global Assessment of Functioning
Scale (GAF) (p , 0.001). Although the difference was not significant, 80% of treatment-resistant
patients with disorganized schizophrenia responded to clozapine.
Conclusion: Patients with the disorganized subtype of schizophrenia should benefit from clozapine
as a second-line agent.
Keywords: Clozapine response; disorganized schizophrenia; treatment-resistant schizophre-
nia; subtypes of schizophrenia; clinical predictors
Introduction
The subtypes of schizophrenia were removed from the
DSM-5.1 The justification of the joint committee was that
these subtypes have shown poor reliability and stability,
and have not supported specific treatment. As an
alternative, a continuum of blended psychopathological
dimensions has been proposed to explain clinical hetero-
geneity.1
In 1881, Hecker described an entity of early onset,
typically during adolescence, characterized by the emer-
gence of mood symptoms before the onset of psychotic
and disorganized symptoms, progressing quickly to
severe functional impairment and cognitive deterioration.
He termed this entity ‘‘hebephrenia.’’ The features of
hebephrenia prepared the ground for Kraepelin’s concept
of dementia praecox and Bleuler’s ‘‘group of schizophre-
nias.’’2 Hebephrenia was also the base for the disorga-
nized subtype criteria operationalized in the DSM-IV,
where it had to satisfy the basic diagnostic criteria for
schizophrenia and show prominence of at least two out of
the following symptoms: disorganized speech, disorga-
nized behavior, and flat or inappropriate affect.3
Few studies have addressed the prognosis of the
disorganized subtype of schizophrenia, and patients with
this subtype seem to respond relatively poorly to
treatment and have a worse long-term prognosis.4,5
Although the use of subtypes has declined over time,6 a
recent study of 8,028 patients showed that disorganized
schizophrenia and delusional disorder had good validity.7
Approximately 30% of patients will be treatment-
resistant (TR) to antipsychotics. On the basis of several
lines of evidence, there is a consensus that clozapine is
the best antipsychotic for TR patients.8
This study aims to ascertain whether patients with
disorganized schizophrenia (DS) are more TR than those
with paranoid schizophrenia (PS), and whether promi-
nence of disorganized symptoms is a predictor of
treatment resistance. Only these subtypes were chosen
because they have shown higher homogeneity and
validity.7
Methods
Subjects
This was an observational study (n=85), with data
collected from consecutive admissions to the inpatient
unit of Hospital das Clı´nicas Luzia de Pinho Melo (Mogi
das Cruzes, state of Sa˜o Paulo, Brazil), which is the
referral hospital for psychiatric admissions in the area
where the study was conducted, between 2011 and 2013.
The inclusion criteria were: 1) presence of PS or DS as
defined by the DSM-IV; 2) a lack of demonstrable organic
brain disease (on computed tomography) or severe
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mental retardation before onset; and 3) age between 12
and 60 years. Other subtypes were excluded, except for
undifferentiated schizophrenia; patients with this subtype
were allocated to the paranoid group or the disorganized
group as seen fit. The study was approved by the local
Ethics Committee, and all subjects and relatives provided
written informed consent.
Diagnostic and symptoms assessment
All patients were administered the Positive and Negative
Syndrome Scale (PANSS), the Global Assessment of
Functioning (GAF) scale, and the Clinical Global
Impression - Severity (CGI-S) scale at baseline. PANSS
and CGI-S were rated again after any switch in
antipsychotic and at discharge. Diagnostic evaluation
was performed with the Structured Clinical Interview for
DSM-IV Axis I Disorders (SCID-I). To ensure accurate
differentiation of the subtypes, the classification into DS
or PS followed the hierarchical criterion of the SCID-I
based on prominence of psychotic symptoms of module
B. Patients presenting prominence of items B1 to B9
(delusion and hallucinations) were classified as PS, and
those presenting prominence of items B11 to B13
(grossly disorganized behavior, grossly inappropriate
affect, and disorganized speech) were classified as DS.
Each psychopathological dimension score was calculated
as the sum of the three most correlated items of the
PANSS: 1) positive dimension = P1 + P3 + P6 (delusions,
hallucinatory behavior, suspicious); 2) disorganized
dimension = P2 + G10 + G11 (conceptual disorganiza-
tion, disorientation, poor attention); 3) negative dimension
= N1 + N2 + N3 (blunted affect, emotional withdrawal,
poor rapport).
Antipsychotic treatment and TR criteria
Response was defined as a reduction of more than 40%
in the baseline total PANSS score (subtracting the 30
initial points).9 Treatment resistance was defined as an
absence of response to two trials of antipsychotic
(haloperidol, olanzapine, risperidone, or quetiapine). In
this case, clozapine or combination therapy was intro-
duced. The switch to a new antipsychotic occurred in
three situations: 1) absence of response after 4 weeks on
any antipsychotic; 2) absence of response after 2 weeks
on a previously trialed drug (full adherence before
hospitalization reported by relatives); or 3) intolerance
to side effects. All patients were rated by the first author,
who was not blind to the subtype or to the choice of first
medication.
Statistical analysis
The percentages of treatment resistance and response to
clozapine, mean scores on the PANSS, CGI-S, and GAF
scales, and socio-demographic data were compared
between the DS and PS groups. The mean scores of
the three psychopathological dimensions, age of onset,
and duration of illness were controlled for treatment
resistance. Statistical analyses were performed with
SPSS version 17.0. Bivariate statistical analyses were
performed using the most adequate statistical test for
each situation (Fisher’s exact test or Student’s t-test for
unequal variances). A p-value of , 0.05 was considered
significant.
Results
Eight patients (9%) were excluded from the study,
whereof three were subtyped as catatonic and five as
residual. Only three of them were TR. The remaining
sample comprised 25 (29.5%) patients with DS and 60
(70.5%) with PS. No differences were observed between
the groups with respect to sex, age at hospitalization, and
duration of illness. On the other hand, patients in the DS
group were significantly more TR than those in the PS
group, presented worse scores in the PANSS, CGI-S,
and GAF (p , 0.01), and were younger at onset. After
controlling for all TR patients, no such difference was
found for earlier age of onset (p = 0.11) or duration of
illness (p = 0.28). With respect to symptom dimensions,
only the disorganized dimension (p = 0.004) was higher in
the TR subgroup.
Clinical and demographic data are presented in Table 1.
Discussion
To the best of our knowledge, this was the first study to
compare treatment resistance between two subtypes of
Table 1 Clinical and demographic data comparing disorganized with paranoid subtype
Clinical and demographic variables Disorganized Paranoid p-value
Number of patients (%) 25 (29.5%) 60 (70.5%) -
TR (%) 15 (60%) 12 (20%) 0.001
PANSS (mean 6 SD) 145.2616.0 126.3616.7 , 0.001
CGI-S (mean 6 SD) 6.660.49 5.860.61 , 0.001
GAF (mean 6 SD) 12.266.6 24.167.4 , 0.001
Gender, male (%) 14 (56.0%) 34 (56.7%) 1.00
Age, years (mean 6 SD) 32.1611.7 33.0612.1 0.54
Age at onset, years (mean 6 SD) 19.166.0 24.569.2 0.01
DI, years (mean 6 SD) 12.8610.1 9.469.3 0.15
Response to clozapine in TR group (%) 12 (80.0%) 8 (66.3%) 0.66
CGI-S = Clinical Global Impression Scale; DI = duration of illness; GAF = Global Assessment of Functioning Scale; PANSS = Positive and
Negative Syndrome Scale; SD = standard deviation; TR = treatment-resistant.
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schizophrenia using quantitative rating scales in an
observational setting. While previous studies have not
identified unequivocal clinical predictors of antipsychotic
response, with regards to non-response, there is con-
sistent evidence for the duration of untreated psychosis,
poor premorbid function, and severity of the negative and
cognitive/disorganized symptom dimensions as predic-
tors.10,11 In our results, the nonsignificant longer duration
of illness and earlier age of onset among refractory
patients would possibly be significant in a larger sample.
On the other hand, disorganization was significantly
predictive of treatment resistance even in a dimensional
approach.
The observation that 80% of refractory DS responded
to clozapine highlights the effectiveness of this medica-
tion in such patients. However, the literature on response
to clozapine in patients with disorganization remains
unclear. Joffe et al.12 conducted a retrospective study of
outpatients treated with clozapine, and those with the
disorganized subtype showed greater clinical (p = 0.032)
and social (p = 0.024) improvements than non-disorga-
nized patients. In a recent study designed to investigate
trends in clozapine prescription, Nielsen et al.13 found
higher prescription rates of clozapine for patients with DS.
The percentage of disorganized patients taking clozapine
was 29.7%, while only 11.3% of those with PS were on
the drug (p , 0.001). On the other hand, Rodriguez et
al.,14 found disorganization to be associated with non-
response and partial response.
This study is limited by the small sample and the
expectation bias of the rater. However, the observational
follow-up design has the advantage of providing a picture
consistent with clinical practice. Taking into account these
preliminary results added to the reports listed above, the
authors propose the use of clozapine as a second-line
agent in DS. Definition of more reliable categorical
subtypes is desirable, since the current opinion in DSM-
5 regards only the dimensional view.
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